Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Apellis Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers APLS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.